Compare · IMRX vs NVO
IMRX vs NVO
Side-by-side comparison of Immuneering Corporation (IMRX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IMRX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $222.81B, about 742.2x IMRX ($300.2M).
- IMRX has been more active in the news (6 items in the past 4 weeks vs 5 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 19 for IMRX).
- Company
- Immuneering Corporation
- Novo Nordisk A/S
- Price
- $4.63-2.94%
- $50.31-2.25%
- Market cap
- $300.2M
- $222.81B
- 1M return
- +12.93%
- -
- 1Y return
- +12.38%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 6
- 5
- Recent ratings
- 19
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest IMRX
- SEC Form 4 filed by Chief Financial Officer Gengos Andrew
- Immuneering Corporation Announces Grants of Inducement Awards
- New insider Gengos Andrew claimed ownership of 225,000 shares (SEC Form 3)
- Cantor Fitzgerald initiated coverage on Immuneering with a new price target
- Kalaris Appoints Laurie Keating to Board of Directors
- PRESIDENT AND CEO Zeskind Benjamin J. bought $10,948 worth of shares (2,400 units at $4.56), increasing direct ownership by 0.10% to 2,315,252 units (SEC Form 4)
- CHIEF SCIENTIFIC OFFICER Hall Brett Matthew bought $25,045 worth of shares (6,035 units at $4.15), increasing direct ownership by 2% to 382,531 units (SEC Form 4)
- Immuneering Corporation filed SEC Form 8-K: Leadership Update
- Immuneering Appoints Andrew Gengos as Chief Financial Officer
- SEC Form 4 filed by Director Schall Thomas J.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S